Literature DB >> 19006068

Ultrasound treatment of cutaneous side-effects of infused apomorphine: a randomized controlled pilot study.

Leon Poltawski1, Hazel Edwards, Amy Todd, Tim Watson, Andrew Lees, Cherry Ann James.   

Abstract

Apomorphine hydrochloride is a dopamine agonist used in the treatment of advanced Parkinson's disease. Its administration by subcutaneous infusions is associated with the development of nodules that may interfere with absorption of the drug. This pilot study assessed the effectiveness of ultrasound (US) in the treatment of these nodules. Twelve participants were randomly assigned to receive a course of real or sham US on an area judged unsuitable for infusion. Following treatment, no significant change was observed in measures of tissue hardness and tenderness. However, 5 of 6 participants receiving real US rated the treated area suitable for infusion compared with the 1 of 6 receiving sham US. Sonographic appearance improved in both groups, but more substantially in the real US group. Power calculations suggest a total sample size of 30 would be required to establish statistical significance. A full-scale study of the effectiveness of therapeutic US in the treatment of apomorphine nodules is warranted.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19006068     DOI: 10.1002/mds.22316

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  5 in total

Review 1.  Old Drugs, New Delivery Systems in Parkinson's Disease.

Authors:  Harsh V Gupta; Kelly E Lyons; Rajesh Pahwa
Journal:  Drugs Aging       Date:  2019-09       Impact factor: 3.923

2.  A Novel Method of Treating Apomorphine-Induced Subcutaneous Nodules.

Authors:  Sabela Novo Ponte; Celia García Malo; Maria Rosario Blasco Quílez; Pilar Sánchez Alonso
Journal:  Mov Disord Clin Pract       Date:  2019-11-17

Review 3.  Pharmacological Insights into the Use of Apomorphine in Parkinson's Disease: Clinical Relevance.

Authors:  Manon Auffret; Sophie Drapier; Marc Vérin
Journal:  Clin Drug Investig       Date:  2018-04       Impact factor: 2.859

4.  Apomorphine formulation may influence subcutaneous complications from continuous subcutaneous apomorphine infusion in Parkinson's disease.

Authors:  Peter Hagell; Arja Höglund; Carina Hellqvist; Eva-Lena Johansson; Berit Löwed; Anne-Christine Sjöström; Carina Karlberg; Margareth Lundgren; Nil Dizdar; Anders Johansson; Thomas Willows; Johan Rådberg; Filip Bergquist
Journal:  J Neurol       Date:  2020-07-01       Impact factor: 4.849

Review 5.  The Skin and Parkinson's Disease: Review of Clinical, Diagnostic, and Therapeutic Issues.

Authors:  Matej Skorvanek; Kailash P Bhatia
Journal:  Mov Disord Clin Pract       Date:  2016-09-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.